

Contemporary Treatment of Endometrial Cancer – Clinical Brief #2

References

Tweet 10

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Uterine Neoplasms (v1.2022). Updated November 4, 2021. Accessed March 29, 2022. https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf

Tweet 12

O'Malley DM, Bariani GM, Cassier PA, et al. Pembrolizumab in patients with microsatellite instability-high advanced endometrial cancer: results from the KEYNOTE-158 study. *J Clin Oncol*. 2022;40(7):752-761. doi:10.1200/JCO.21.01874

Tweet 13

JEMPERLI (dostarlimab-gxly) [prescribing information]. GlaxoSmithKline. Approved 2021. Revised April 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761174s002lbl.pdf

Oaknin A, Gilbert L, Tinker AV, et al. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study. *J Immunother Cancer*. 2022;10(1):e003777. doi:10.1136/jitc-2021-003777

Oaknin A, Pothuri B, Gilbert L, et al. Dostarlimab in advanced/recurrent (AR) mismatch repair deficient/microsatellite instability-high or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC): The GARNET study. *J Clin Oncol*. 2022;40(16_suppl):5509-5509. doi:10.1200/JCO.2022.40.16_suppl.5509

Tweet 14

JEMPERLI (dostarlimab-gxly) [prescribing information]. GlaxoSmithKline. Approved 2021. Revised April 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761174s002lbl.pdf

KEYTRUDA® (pembrolizumab) [prescribing information]. Merck Sharp & Dohme Corp. Approved 2014. Revised March 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125514s110lbl.pdf

Tweet 15

O'Malley DM, Bariani GM, Cassier PA, et al. Pembrolizumab in patients with microsatellite instability-high advanced endometrial cancer: results from the KEYNOTE-158 study. *J Clin Oncol*. 2022;40(7):752-761. doi:10.1200/JCO.21.01874

Oaknin A, Gilbert L, Tinker AV, et al. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study. *J Immunother Cancer*. 2022;10(1):e003777. doi:10.1136/jitc-2021-003777

Oaknin A, Pothuri B, Gilbert L, et al. Dostarlimab in advanced/recurrent (AR) mismatch repair deficient/microsatellite instability–high or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC): The GARNET study. *J Clin Oncol*. 2022;40(16_suppl):5509-5509. doi:10.1200/JCO.2022.40.16_suppl.5509

Tweet 16

Brahmer JR, Abu-Sbeih H, Ascierto PA, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. *J Immunother Cancer*. 2021;9(6):e002435. doi:10.1136/jitc-2021-002435

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Management of Immunotherapy-Related Toxicities (v1.2022). Updated February 28, 2022. Accessed May 6, 2022. https://www.nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf

Schneider BJ, Naidoo J, Santomasso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. *J Clin Oncol*. 2021;39(36):4073-4126. doi:10.1200/JCO.21.01440

Glossary

AE, adverse event
aEC, advanced endometrial cancer
ALT, alanine transaminase
AST, aspartate aminotransferase
BMI, body mass index
CI, confidence interval
dMMR, deficient mismatch repair
EC, endometrial cancer
IHC, immunohistochemistry
IO, immunotherapy
irAE, immune-related adverse event
mDOR, median duration of response
mOS, median overall survival
mPFS, median progression-free survival
MSI-H, microsatellite instability-high
NCCN, National Comprehensive Cancer Network
NR, not reached
ORR, objective response rate
OS, overall survival
PFS, progression-free survival
Q3W, once every three weeks
TRAE, treatment-related adverse event
w/, with